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Abstract
Hypersensitivity pneumonitis (HP) is a pulmonary disease with symptoms of dyspnea and cough
resulting from the inhalation of an antigen to which the subject has been previously sensitized. The
incidence of HP is unknown. A population-based study estimated the annual incidence of interstitial
lung diseases as 30:100,000 and HP accounted for less than 2% of these cases. The diagnosis of HP
can often be made or rejected with confidence, especially in areas of high or low prevalence
respectively, using simple diagnostic criteria. Chest X-rays may be normal in active HP; High
Resolution Computed Tomography is sensitive but not specific for the diagnosis of HP. The primary
use of pulmonary function tests is to determine the physiologic abnormalities and the associated
impairment. Despite the pitfalls of false positive and false negatives, antigen-specific IgG antibodies
analysis can be useful as supportive evidence for HP. Bronchoalveolar lavage plays an important role
in the investigation of patients suspected of having HP. A normal number of lymphocytes rules out
all but residual disease. Surgical lung biopsy should be reserved for rare cases with puzzling clinical
presentation or for verification the clinical diagnosis when the clinical course or response to
therapy is unusual. Being an immune reaction in the lung, the most obvious treatment of HP is
avoidance of contact with the offending antigen. Systemic corticosteroids represent the only
reliable pharmacologic treatment of HP but do not alter the long-term outcome. The use of inhaled
steroids is anecdotal. Treatment of chronic or residual disease is supportive.
Disease name and synonyms
Hypersensitivity pneumonitis – Extrinsic allergic alveolitis
Definition
Hypersensitivity pneumonitis (HP) is a pulmonary dis-
ease with symptoms of dyspnea and cough resulting from
the inhalation of an antigen to which the subject has been
previously sensitized. Acute and subacute HP represent
the most active forms of the disease which may become
chronic while remaining progressive. HP may also evolve
to end-stage lung [1]. The diagnosis of HP has most often
relied on an array of nonspecific clinical symptoms and
signs developed in an appropriate setting [2], with the
demonstration of interstitial markings on chest radio-
graphs, serum antibodies against offending antigens, a
lymphocytic alveolitis on bronchoalveolar lavage (BAL),
and/or a granulomatous reaction on lung biopsies.
Etiology
A wide spectrum of antigens may trigger the disease. These
antigens have often led to a graphic and most descriptive
nomenclature detailed in several case reports. A complete
review of these antigens is beyond the scope of this article.
The offending antigens can be classified in five broad cat-
egories represented by disease prototypes (Table 1).
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Epidemiology
Like most interstitial lung diseases, HP is a rare disease. In
a population-based study, the estimated annual incidence
of interstitial lung disease was reported as 30 per 100,000
[3]. In that study, HP accounted for less than 2% of the
incident cases. The study was conducted in New Mexico, a
dry environment that is not propitious to the develop-
ment of many forms of HP. In the HP Study [4], 30% of
the 661 patients included in this prospective multi-center
cohort had HP. This cohort study included consecutive
adult patients presenting with a pulmonary syndrome for
which active HP was considered in the differential diagno-
sis.
Over the last two or three decades, the difficulties in stud-
ying the epidemiology of HP have been illustrated by
studies of the incidence or prevalence of farmer's lung.
Definite conclusions have been elusive because of meth-
odological issues including study design and the defini-
tion of farmer's lung [5-7]. Most studies used cross-
sectional surveys in order to determine the prevalence of
farmer's lung or that of associated conditions such as the
presence of precipitating antibodies against offending
antigens. Few, if any, real cohort studies have been pub-
lished on the incidence of the disease [8-10]. An even
more important factor has been the lack of a consistent
definition of farmer's lung. Epidemiological reports based
on cases admitted to a hospital where a definite diagnosis
can be made using chest radiographs, computed tomogra-
phy, BAL and/or lung biopsies are likely to identify the
most severe cases only and thus underestimate the true
prevalence of the disease. In addition, important differ-
ences have been observed in the classification of respira-
tory diseases among farmers by clinicians from different
European countries [11]. In a survey of final diagnostic
classifications on hospital discharge, 73% of cases of HP
were erroneously classified [12]. Finally, fluctuations in
the prevalence of farmer's lung have been related to a
greater diagnostic suspicion attributable to ongoing epi-
demiological surveys [13]. Despite these methodological
limitations, several studies gave consistent results allow-
ing the prevalence of farmer's lung in exposed farmers to
be estimated at between 0,5 and 3% [14-19].
The difficulties in establishing the incidence and preva-
lence of HP are further complicated by geographic varia-
bles, including climatic conditions and, in the case of
farmer's lung, farming practices. Sex differences for both
HP and seropositivity are likely to represent differences in
exposure to offending antigens [20-22]. Genetic markers
have generally failed to confirm hereditary risk factors for
HP [23-33].
Diagnostic criteria/Clinical presentation
A number of diagnostic criteria recommendations for HP
have been published [34-37] (Table 2). The most widely
used are those from Richerson and colleagues [35]. None
of these sets of criteria have been validated. Their diagnos-
tic accuracy is therefore unknown. They correspond in
effect to definitions of the disease.
Others have developed prediction rules (i.e., clinical tools
that quantify the contribution of various components of
the history, physical examination and basic laboratory
results to the diagnosis in an individual patient [38]) for
periodic surveillance in high-risk workers or case finding
in outbreaks of HP [39-41]. Although these rules are
meant to be sensitive (i.e., able to detect most cases of
work-related HP), it is likely that their specificity is limited
in work environments with a high prevalence of other res-
piratory diseases. Little information is provided for their
accuracy.
The HP study
We recently addressed the issue of the clinical diagnostic
criteria of HP in a prospective multi-centre cohort study
[4]. Its objective was to develop a clinical prediction rule
for the diagnosis of active HP. Such a rule aims at helping
clinicians to arrive at a more accurate estimate of proba-
bility of HP and decide whether further investigation is
needed to either rule in or rule out HP.
Consecutive adult patients presenting with a pulmonary
syndrome for which active HP was considered in the dif-
ferential diagnosis were included in this study. This cohort
thus included a wide range of patients presenting for the
investigation of a suspected interstitial lung disease,
including patients with HP (the «cases») and patients
Table 1: Prototypes of hypersensitivity pneumonitis according to major classes of antigens
Class of antigens Specific antigen Disease
Bacteria Saccharopolyspora rectivirgula Farmer's lung
Fungus Trichosporon cutaneum Summer-type HP
Mycobacteria Mycobacterium avium intracellulare Hot-tub lung
Proteins Altered pigeon serum (probably IgA) Pigeon breeder's disease
Chemical products Diphenylmethane diisocyanate (MDI) MDI HPOrphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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without HP (the «controls»). Regression analyses identi-
fied six significant predictors of active HP (Table 3).
The clinical prediction model produced an equation
expressing the probability of HP as a function of the sta-
tistically significant variables. From this equation, we con-
structed a table of probability for combinations of
predictors (Table 4). In clinical practice, the best diagnos-
tic strategy will depend on the probability of HP deter-
mined from Table 4.
For instance, in a farmer presenting with recurrent epi-
sodes of respiratory symptoms, inspiratory crackles and
testing positive for the corresponding precipitating anti-
bodies, the probability of HP would be 81% (Table 4).
Another patient presenting with progressive dyspnea and
inspiratory crackles as the unique criteria of HP would
have a probability of HP of less than 1%. Further investi-
gation would be mandated only in the former. Typical
findings of an alveolar lymphocytosis and/or bilateral
ground-glass opacities on HRCT in the former patient
would secure the diagnosis of HP, without resorting to
surgical lung biopsy. HP would be confidently ruled out
in the latter and the investigation oriented towards
another diagnosis.
Classification of HP
Much confusion still surrounds the classification of HP.
Its clinical presentations have classically been defined as
acute, subacute and chronic [35]. In the acute form, influ-
enza-like symptoms often predominate, consisting of
chills, fever, sweating, myalgias, lassitude, headache, and
nausea that begin 2 to 9 hours after exposure, peak typi-
cally during 6 and 24 hours, and last from hours to days.
Respiratory symptoms such as cough and dyspnea are
common but not universal. The subacute form may
appear gradually over several days to weeks, is marked by
cough and dyspnea, and may progress to severe dyspnea
and cyanosis, leading to urgent hospitalization. The
chronic form has an insidious onset over a period of
months, with increasing cough and exertional dyspnea.
Fatigue and weight loss may be prominent symptoms.
The distinction between the stages of HP is often difficult
as they likely represent different manifestations of a single
disease that may be related more to the pattern of antigen
exposure than to the offending antigen itself. This state-
ment is supported by the finding of considerable overlap
in the clinical manifestations of patients with farmer's
lung (usually considered as the prototype of acute HP)
and those with pigeon breeder's or bird fancier's diseases
(the prototypes of subacute and chronic HP, respectively)
[42]. Also, chronic HP may still be active and progressive.
Others have suggested a classification that takes into
Table 2: Proposed diagnostic criteria for hypersensitivity pneumonitis for clinical purposes
Author Major criteria Minor criteria
Terho [10] 1. exposure to offending antigens (revealed by history 
aerobiological or microbiological investigations of the 
environment, or measurements of antigen-specific IgG 
antibodies)
2. symptoms compatible with HP present and appearing or 
worsening some hours after antigen exposure;
3. lung infiltrations compatible with HP visible on chest X-ray
1. basal crepitant rales
2. impairment of the diffusing capacity
3. oxygen tension (or saturation) of the arterial blood either 
decreased at rest, or normal at rest but decreased during 
exercise
4. restrictive ventilation defect in the spirometry
5. histological changes compatible with HP
6. positive provocation test whether by work exposure or by 
controlled inhalation challenge
Richerson et al. [35] 1. the history and physical findings and pulmonary function 
tests indicate an interstitial lung disease
2. the X-ray film is consistent
3. there is exposure to a recognized cause
4. there is antibody to that antigen
Cormier et al. [36] 1. appropriate exposure
2. inspiratory crackles
3. lymphocytic alveolitis (if BAL is done)
4. dyspnea
5. infiltrates on chest radiographs or High Resolution 
Computed Tomography (HRCT)
1. recurrent febrile episodes
2. decreased Diffusing Capacity Test (DLCO)
3. precipitating antibodies to HP antigens
4. granulomas on lung biopsy (usually not required)
5. improvement with contact avoidance or appropriate 
treatment
Schuyler et al. [37] 1. symptoms compatible with HP
2. evidence of exposure to appropriate antigen by history or 
detection in serum and/or BAL fluid antibody
3. findings compatible with HP on chest radiograph or HRCT
4. BAL fluid lymphocytosis
5. pulmonary histologic changes compatible with HP
6. positive «natural challenge»
1. bibasilar rales
2. decreased DLCO
3. arterial hypoxemia, either at rest or during exerciseOrphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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account the progression of the disease (acute intermittent,
acute progressive, chronic progressive, chronic nonpro-
gressive) that can only be assessed retrospectively [1,5].
For practical purposes, we have already suggested to con-
sider HP patients as having either active or residual dis-
ease, the latter representing late emphysematous or
fibrotic sequelae of the disease in which the typical alveo-
lar lymphocytosis of active HP has disappeared [4].
Chest radiology
￿ Chest X-ray: Chest radiography is often the initial step in
the investigation of a patient presenting with a pulmonary
syndrome suggestive of HP. The first objective of chest X-
rays is not to rule in HP but rather to rule out other dis-
eases for the patient's illness. In acute HP, one expects to
find groundglass infiltrates, nodular and/or striated
patchy opacities [43,44]. The distribution of these infil-
trates is usually diffuse but often sparing the bases in the
subacute form [45]. A variety of different distributions
have been described [46,47]. None of these findings are
specific to HP. Up to 20% of individuals with acute HP
have normal chest X-rays [48].
￿ CT scanning: Our ability to judge the usefulness of High
Resolution Computed Tomography (HRCT) in HP is lim-
ited by the small number of cases studied. Table 5 summa-
rizes selected reports of HRCT findings according to the
phase of disease. The described patterns are not specific
but suggest that HP may be considered in the differential
diagnosis when present. For instance, groundglass opaci-
ties can be seen in a variety of other diseases including
desquamative interstitial pneumonitis, Pneumocystis cari-
Table 4: Probability (%) of having hypersensitivity pneumonitis*
Exposure to a 
known 
offending 
antigen
Recurrent 
episodes of 
symptoms
Symptoms 4–8 
hours after 
exposure
Weight loss Crackles
+-
Serum precipitins Serum precipitins
+-+-
++++ 9 8 % 9 2 % 9 3 % 7 2 %
+ + + - 97% 85% 87% 56%
+ + - + 90% 62% 66% 27%
+ + - - 81% 45% 49% 15%
+ - + + 95% 78% 81% 44%
+ - + - 90% 64% 68% 28%
+ - - + 73% 33% 37% 10%
+ - - - 57% 20% 22% 5%
- + + + 62% 23% 26% 6%
- + + - 45% 13% 15% 3%
-+-+ 1 8 % 4 % 5 % 1 %
- + - -1 0 % 2 %2 %0 %
- - + + 33% 8% 10% 2%
- - + -2 0 % 4 %5 %1 %
- - - + 6% 1% 1% 0%
- - - - 3% 1% 1% 0%
* All the predictors are dichotomous variables; - indicates absent; +, present; from Lacasse et al. [4], with permission.
Table 3: Significant predictors of hypersensitivity pneumonitis*
Variables Odds ratio Confidence interval (95%)
Exposure to a known offending antigen 38.8 11.6 – 129.6
Positive precipitating antibodies 5.3 2.7 – 10.4
Recurrent episodes of symptoms 3.3 1.5 – 7.5
Inspiratory crackles 4.5 1.8 – 11.7
Symptoms 4–8 hours after exposure 7.2 1.8 – 28.6
Weight loss 2.0 1.0 – 3.9
* From Lacasse et al. [4], with permission.Orphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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nii pneumonia, bronchiolitis obliterans with organizing
pneumonia, bronchoalveolar carcinoma, alveolar protei-
nosis, and alveolar hemorrhage. Conversely, when
groundglass opacities are associated with poorly defined,
centrilobular micronodules and mosaic attenuation or
expiratory air trapping, the diagnosis of HP is further sup-
ported, but such an association is rare.
Pulmonary function tests
The primary use of pulmonary function tests is to deter-
mine the physiologic abnormalities and the associated
impairment. The results of pulmonary function tests may
also guide therapy by helping the clinician to select those
for whom a treatment with corticosteroids may be justi-
fied. Pulmonary function tests have no discriminative
properties in differentiating HP from other interstitial
lung diseases [4].
The typical physiological profile of acute HP is a restrictive
pattern with low DLCO [53]. In chronic disease, the pat-
tern can be restrictive, but at least in farmer's lung, the
most frequent profile is an obstructive defect resulting
from emphysema [54]. The currently held belief is that a
decreased DLCO is always present in HP [55]. Neverthe-
less, in the HP Study, 39 of the 177 patients (22%) in
whom DLCO could be measured had normal results
(defined as a DLCO 80% predicted) at the time of diagno-
sis [HP Study Group, unpublished data].
Specific antibodies
The usefulness of most reports on the sensitivity and spe-
cificity of serum specific antibodies is limited by the inclu-
sion of inappropriate controls, often healthy subjects. HP
cannot be ruled in solely on the basis of positive antibod-
ies or ruled out on the basis of negative antibodies. Many
asymptomatic farmers (10%) and pigeon breeders (40%)
have positive results [5,23,56] and many HP patients are
negative for specific antibodies [57]. It is unclear if HP can
occur in the absence of specific antibodies to the respon-
sible allergen. False negatives could result from testing for
inappropriate antigens.
Despite the pitfalls discussed above, specific antibodies
analysis can be useful as supportive evidence. The results
of the HP Study demonstrate that positive serum antibod-
ies are a significant predictor of HP (odds ratio: 5.3; 95%
CI: 2.7 – 10.4) [4]. Antigens available for testing in most
centers included pigeon and parakeet sera, dove feather
antigen, Aspergillus sp, Penicillium, Saccharopolyspora recti-
virgula, and Thermoactinomyces viridans. These antigens
cover most cases of HP including pigeon breeder's disease,
bird fancier's lung, farmer's lung, and humidifier lung.
The antigen Trichosporon cutaneum is also available in
Japan for cases of summer-type HP [58]. The selection of
antigens to be tested often needs to be determined locally
according to the prevalent antigens [4,59]. In Eastern
France, by using a panel of antigens really responsible for
farmer's lung and not a classical standardized panel, sero-
logical tests showed a high rate of sensitivity and specifi-
city [60].
Several methods for determination of precipitins or total
IgG antibodies (immunodiffusion, immunoelectrophore-
sis, enzyme-linked immunosorbant assays [ELISA]) and
Table 5: High-resolution computed tomography findings in hypersensitivity pneumonitis
Stage of disease References Sample size Findings *
Acute Cormier et al. [49] N = 20 (farmer's lung) • ground-glass opacities
• micronodules
• mosaic perfusion
• emphysema
• honeycombing
• mediastinal lymphadenopathis
Subacute Hansell et al. [50] N = 17 (including 9 with pigeon breeder's 
disease and 4 with farmer's lung)
• generalized increase in attenuation of the lung
• nodular pattern
• reticular pattern
• patchy air space opacification
Remy-Jardin et al. [51] N = 21 (pigeon breeder's disease) • micronodular pattern (< 5 mm in diameter)
• ground-glass attenuation
• emphysematous changes
• honeycombing
Chronic Adler et al. [52] N = 16 (antigen = ?) • fibrosis
• ground-glass attenuation
• nodules
Remy-Jardin et al. [51] N = 24 (pigeon breeder's disease) • honeycombing
• ground-glass attenuation
• micronodules
• emphysema
* The findings are ranked according to their decreasing order of prevalence in the study population.Orphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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different antigen preparations have been described
[61,62]. ELISA is usually the preferred method. Unfortu-
nately, even the ELISA technique lacks standardization
[63].
Inhalation challenge
Inhalation challenges to suspected environments, usually
at the workplace, as well as specific provocation tests in
controlled conditions have been described [64]. These
tests lack standardization both in the inhalation protocols
and in the criteria defining a positive response. Further
studies are needed before recommending inhalation chal-
lenges in the diagnosis of HP.
Bronchoalveolar lavage
BAL plays an important role in the investigation of
patients suspected of having HP [65]. BAL can provide
useful, supportive elements in the diagnosis of HP. A nor-
mal number of lymphocytes rules out all but residual dis-
ease [66]. However, the presence of an alveolar
lymphocytosis does not, by any means, establish the diag-
nosis because asymptomatic, exposed individuals can also
have increased numbers of lymphocytes in their BAL [67].
These individuals do not have subclinical HP, as con-
firmed by a 20-year follow-up [68]. Also many other dis-
eases (including sarcoidosis, interstitial pneumonia
associated with collagen vascular disease, silicosis, bron-
chiolitis obliterans with organizing pneumonia, HIV-
associated pneumonitis and drug-induced pneumonitis)
are characterized by an alveolar lymphocytosis [65]. Posi-
tive BAL findings (specially if the observed lymphocytosis
is marked) [67,68] in a patient with interstitial lung dis-
ease of unknown origin should direct the clinician
towards the possible diagnosis of HP [65].
Table 6: Distribution of diagnoses in the HP Study [4]
Diagnosis Number of patients
Hypersensitivity pneumonitis 199
Pigeon breeder's/bird fancier's disease 132
Farmer's lung 38
Humidifier lung 3
Suberosis 2
Summer type HP 2
Various exposures to fungi 19
HP of unknown origin 3
Controls 462
Idiopathic interstitial pneumonia * 226
Sarcoidosis 52
Interstitial disease associated with collagen vascular disease 35
Drug induced pulmonary disease 26
Bronchiolitis obliterans (with our without organizing pneumonia) 25
Unspecified interstitial lung disease † 26
Infectious pneumonia 11
Histiocytosis X 10
Asthma 6
Silicosis 5
Eosinophilic pneumonia 5
Normal lung 4
Bronchoalveolar carcinoma/carcinomatous lymphangitis 4
Residual HP ‡ 3
Residual HP ‡ 3
Organic dust toxic syndrome 3
Lymphocytic interstitial pneumonia 2
Pulmonary edema (heart failure) 2
Radiation pneumonitis 2
Miscellaneous § 13
TOTAL 661
* includes patients with the clinical diagnosis of idiopathic pulmonary fibrosis, and those with the pathological diagnoses of usual, desquamative, 
respiratory bronchiolitis, acute and non-specific interstitial pneumonia;
† includes patients in whom no specific diagnosis could be reached but in whom HP was excluded on the basis of BAL;
‡ includes late emphysematous or fibrotic sequelae of HP in which the typical alveolar lymphocytosis of active HP has disappeared;
§includes single cases of alveolar hemorrhage, anthracosis, berylliosis, Churg-Strauss syndrome, diffuse panbronchiolitis, hepato-pulmonary 
syndrome, HIV-associated nonspecific interstitial pneumonia, necrotizing sarcoid granulomatosis, pulmonary amyloidosis, alveolar proteinosis, crack 
lung, Pneumocystis carinii pneumonia, and Wegener's granulomatosis.Orphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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As in the case of serum precipitins and inhalation chal-
lenge, the BAL technique lacks standardization. Lym-
phocyte subsets, especially the CD4/CD8 ratio and
activation were previously thought to be helpful in differ-
entiating HP from sarcoidosis. This is now challenged
since the CD4/CD8 ratio in HP can be as high as that seen
in sarcoidosis [71-73]. A low ratio would however support
HP over sarcoidosis.
Lung biopsy
The histopathology of HP has been well described [74-
76]. In the acute stages, reports on open lung biopsies
revealed features of interstitial lymphocytes infiltrates and
fibrosis, edema, noncaseating granulomas, and bronchi-
olitis obliterans. Macrophages with foamy cytoplasm are
also found within the alveolar space. In chronic stages,
widespread fibrotic reaction is a prominent feature, often
without predominant involvement of upper lobes with
contraction. Even though emphysema was found at
necropsy in chronic HP, it is only recently that emphy-
sema has been recognized as a long-term complication of
HP [54].
￿ Transbronchial biopsy: Hematoxylin-eosin-stained
transbronchial biopsy is of limited usefulness for the diag-
nosis of farmer's lung [77].
￿ Surgical lung biopsy: The utility of surgical lung biopsy
has most often been reported in terms of "diagnostic
yield", i.e., the proportion of specific diagnoses obtained
from the procedure. Whether the procedure alters the clin-
ical management represents an important outcome. Sev-
eral retrospective studies addressing these issues in series
of patients with a variety of diffuse parenchymal diseases
are available [78-89]. In selected reports, the results have
been very heterogeneous: the diagnostic yield ranged
from 34% to 100%; therapy was altered in 46% to 75% of
the cases. This heterogeneity may stem from several fac-
tors, including the selection of candidates to open lung
biopsy, the timing of the procedure along the course of
the disease, as well as the expertise of the attending
pathologist. The decision to submit a patient to open lung
biopsy must be balanced against the associated morbidity.
If HP is suspected, it has been our recommendation to
reserve surgical lung biopsy for rare cases with puzzling
clinical presentation or for verification the clinical diagno-
sis when the clinical course or response to therapy is unu-
sual [36]. This recommendation is not based on evidence
but emphasizes the limitations of surgical lung biopsy
and the necessity of a thorough clinical investigation that
comprises a high index of suspicion and a careful expo-
sure history.
Differential diagnosis
The differential diagnosis of HP is wide. The results of the
HP Study illustrate this situation [4]. In this cohort study,
consecutive adult patients presenting with a pulmonary
syndrome for which active HP was considered in the dif-
ferential diagnosis were included. The investigators had to
classify each patient as HP or non-HP (i.e., control). The
control group may be regarded as a set of lung diseases
that must be distinguished from HP (Table 6).
Management
Treatment
As HP is a hyper immune reaction of the lung, the most
obvious treatment is avoidance of contact with the anti-
gen. Systemic corticosteroids represent the only recog-
nised pharmacologic treatment for HP. The best available
evidence comes from a unique randomized placebo-con-
trolled trial [90]. In this trial, 36 patients with acute
farmer's lung were randomized to receive either 40 mg of
Prednisolone tapering over 8 weeks or placebo. All
patients were instructed to avoid contact with the farm
during the drug trial. After one month of treatment, there
was no difference in FEV1, FVC and pO2 between the two
groups. However, a small but significant difference in
DLCO was observed. Corticosteroids had no beneficial
effect on the long-term (5-year) prognosis however. The
results of that trial confirmed other observations from
controlled but non-randomized trials [91,92] and case
series: corticosteroids hasten the recovery from the acute
stage of HP, but have no beneficial effect on long-term
prognosis. The decision to treat with corticosteroids may
be guided by the severity of symptoms and physiologic
abnormalities [93]. The use of inhaled steroids is anecdo-
tal [94]. The treatment of chronic or residual disease is
supportive.
Prevention
In high-risk environments (such as farming activities),
education may prevent respiratory problems [95]. Ideally,
all farmers should be informed of the hazards of exposure
to barn dust and encouraged to use adequate preventive
measures. For practical purposes, however, major preven-
tive measures (such as mask wearing, increasing barn ven-
tilation, avoiding the barn when the animals are feeding)
cannot be recommended for primary prevention and are
usually reserved for individuals with past history of HP
[96].
Unresolved questions
A recent workshop of the National Heart, Lung, and Blood
Institute and the Office of Rare Diseases identified several
areas for future clinical research in HP [97]. These include,
among others, (1) the need for a better documentation of
its incidence and prevalence; (2) the identification of
genetic and environmental risk factors that affect its occur-Orphanet Journal of Rare Diseases 2006, 1:25 http://www.OJRD.com/content/1/1/25
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rence and natural history; (3) the validation of biomark-
ers of both exposure and disease; (4) the definition of its
natural history; (5) the development of a battery of stand-
ardized antigens known to cause HP that should be avail-
able to clinicians and researchers for use in both the
diagnosis and investigations of pathogenesis.
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